Raffaele Colombo: sBLA for T-DXd has been accepted by FDA HER2-low or HER2-ultralow breast cancer

Raffaele Colombo shared a post on X:

“sBLA for trastuzumab deruxtecan (T-DXd) has been accepted by FDA (and granted Priority Review) for patients with HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining < IHC 1+) breast cancer after at least one endocrine therapy, based on DESTINY-Breast06.”

Source: Raffaele Colombo/X

Raffaele Colombo, a  leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.